MedTrace Logo

Efficacy and Safety of Herombopag in Patients With Thrombocytopenia Before Hepatectomy

NCT05442632 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 96

Last updated 2024-03-13

No results posted yet for this study

Summary

This is a single center, randomized, controlled study, to evaluate the efficacy and safety of Herombopag in patients with Thrombocytopenia before hepatectomy.

Conditions

  • Hepatopathy

Interventions

DRUG

Hetrombopag

The patients received Hetrombopag 5mg orally d1-14 days, surgery will be conducted at d6-14 day

DRUG

Placebo

The patients received Placebo 5mg orally d1-14 days, surgery will be conducted at d6-14 day

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Lu Wang, Professor · Fudan University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-25
Primary Completion
2025-12-01
Completion
2025-12-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05442632 on ClinicalTrials.gov